715-P: How Frequently Do People with Diabetes Use a Digital Diabetes Logbook and How Satisfied Are They with It?

Abstract

A randomized controlled trial (RCT) was conducted to evaluate the efficacy of a digital diabetes logbook (mySugr) to help with diabetes self-management. Frequency of use as well as satisfaction with the app were assessed. A total of 424 people were included in the RCT with 282 being randomized to the intervention group using the app for 3 months (2:1 randomization) (age: 51.2±14.6 years; 13.1% type 1, 66.7% type 2, 20.2% gestational diabetes). Frequency of use was assessed with user data from the pseudonymized study server. Satisfaction with mySugr was assessed with an adapted version of the Mobile App Rating Scale (MARS). Mean MARS scores were calculated (range: 1-5) with higher scores indicating higher satisfaction. User data from 249 participants of the intervention group (88.3%) were analyzable. The app was used on a median of 92.6% (IQR: 57.7 - 100%) of the study days (median study duration: 91 [IQR: 84-96] days). Over the study duration, participants logged 3.1±2.5 blood glucose values. Satisfaction was very high with a mean MARS score of 4.3±0.7. 64.7% of participants agreed that the app is appealing for people with diabetes and 82.5% agreed that the app is easy to use. Satisfaction was highest in women with gestational diabetes, followed by people with type 1 and people with type 2 diabetes (4.5±0.5 vs. 4.3±0.6 vs. 4.2±0.7; p=0.037). Higher satisfaction was associated with higher percentage of days with app use (r=0.23, p<0.001), higher logging frequency (r=0.20, p=0.002) and less problems with the app (r=-0.20, p=0.001). Those who contacted mySugr support when they had problems were significantly more satisfied than those who did not contact support when they had problems (4.6±0.4 vs. 3.8±0.7, p=0.023). Participants randomized to using mySugr for 3 months (no prior app use) were highly satisfied with the app. Frequency of use of the app across the study period was very high. Satisfaction was high in all diabetes types with women with gestational diabetes having the highest satisfaction. Disclosure N.Hermanns: Advisory Panel; Insulet Corporation, Research Support; Sanofi-Aventis Deutschland GmbH, Roche Diagnostics, Becton, Dickinson and Company, Speaker's Bureau; Dexcom, Inc., Berlin-Chemie AG. D.Ehrmann: Advisory Panel; Roche Diabetes Care, mySugr, Dexcom, Inc., Speaker's Bureau; Berlin-Chemie AG, Dexcom, Inc. S.Silbermann: Employee; Roche Diabetes Care. J.Kober: Employee; mySugr. I.Vesper: None. K.Finke-gröne: None. T.Roos: None. E.Bingol: Employee; Roche Diabetes Care. B.Kulzer: Advisory Panel; Berlin-Chemie AG, Abbott Diabetes, Bayer Inc., Dexcom, Inc., Novo Nordisk, Insulet Corporation, embecta, Research Support; Sanofi, Roche Diabetes Care. Funding Roche Diabetes Care GmbH (DC000097)